Current and future therapy in haemochromatosis and Wilson's disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 12, 2003, Pages 2239-2251

  Murray, Karen F ^b,c   Lam, Dickson ^c   Kowdley, Kris V ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chelation; Haemochromatosis; Thalassaemia; Wilson's disease

Indexed keywords

ASCORBIC ACID; CHELATING AGENT; COPPER; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HLA ANTIGEN CLASS 2; HYDROXYBENZYLETHYLENEDIAMINEDIACETIC ACID; IRON; IRON BINDING PROTEIN; IRON CHELATING AGENT; MELARSOPROL; PENICILLAMINE; PYRIDOXINE; SUCCIMER; TETRATHIOMOLYBDIC ACID; TRIENTINE; UNCLASSIFIED DRUG; VITAMIN K GROUP; ZINC ACETATE;

ABDOMINAL DISTENSION; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTHRALGIA; BONE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COPPER METABOLISM; DISORDERS OF METAL METABOLISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG STRUCTURE; ECCHYMOSIS; EPISTAXIS; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETICS; GINGIVA BLEEDING; GOODPASTURE SYNDROME; GROWTH DISORDER; HEMOCHROMATOSIS; HEMOLYTIC ANEMIA; HUMAN; IRON ABSORPTION; IRON DEFICIENCY; IRON DEPLETION; IRON INTAKE; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIVER DYSFUNCTION; LIVER FIBROSIS; LUNG TOXICITY; METABOLISM; MOLECULAR MECHANICS; MONOTHERAPY; MYASTHENIA GRAVIS; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PERCEPTION DEAFNESS; PHLEBOTOMY; RETINOPATHY; REVIEW; SIDEROBLASTIC ANEMIA; SKIN DISEASE; TERATOGENICITY; THROMBOCYTOPENIA; VOMITING; WILSON DISEASE;

EID: 0347365793     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.12.2239     Document Type: Review

References (114)

1. MERRYWEATHER-CLARKE AT, POINTON JJ, SHEARMAN JD, ROBSON KJ: Global prevalence of putative hematochromatosis mutations. J. Med. Genet. (1997) 34:275-278.
2. LUCOTTE G: Celtic origin of the C282Y mutation of hematochromatosis. Blood Cells Mol. Dis. (1998) 24:433-438.
3. FEDER JN, GNIRKE A, THOMAS W et al.: A novel MHC class 1-like gene is mutated in patients with hereditary hematochromatosis. Nat. Genet. (1996) 13:399-408.
4. BEUTLER E, FELITTI VJ, KOZIOL JA, HO NJ, GELBART T: Penetrance of 845G- > A (C282Y)HFE hereditary hemochromatosis mutation in the USA. Lancet (2002) 359:211-218.
5. GOCHEE PA, POWELL LW, CULLEN DJ, DU SART D, ROSSI E, OLYNYK JK: A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology (2002) 122(3):646-651. Erratum in: Gastroenterology (2002) 122(4):1191.
6. ROETTO A, TOTARO A, CAZZOLLA M et al.: Juvenile hematochromatosis locus maps to chromosome 1q. Am. J. Hum. Genet. (1999) 64:1398-1393.
7. WHITTINGTON CA, KOWDLEY KV: Review article: haemochromatosis. Aliment. Pharmacol. Ther. (2002) 16:19758.
8. ADAMS PC, DEUGNIER Y, MOIRAND R, BRISSOT P: The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology (1997) 25:162-166.
9. ANDREWS NC: Disorders of iron metabolism. N. Engl. J. Med (1999) 341:1986-1995.
10. MCKIE AT, BARROW D, LATUNDE-DADA GO et al.: An iron-regulated ferric reductase associated with the absorption of dietary iron. Science (2001) 291:1755-1759.
11. GUNSHIN H, MACKENZIE B, BERGER UV et al.: Cloning and characterization of a mammalian proton-coupled metal-ion transported. Nature (1997) 388:482-488.
12. MCKIE AT, MARCIANI P, ROLFS A et al.: A novel duodenal iron-regulated transporter, IREG 1, implicated in die basolateral transfer of iron to the circulation. Molec. Cell (2000) 5:299-309.
13. ABBOUD S, HAILE DJ: A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. (2000) 275:19906-19912.
14. VULPE CD, KUO YM, MURPHY TL et al.: Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. (1999) 21:195-199.
15. GARRICK MD, NUNEZ MT, OLIVARES M, HARRIS ED: Parallels and contrasts between iron and copper metabolism. Biometals (2003) 16:1-8.
16. FINCH C: Regulators of iron balance in humans. Blood (1994) 84:1697-1702.
17. ROY CN, ENNS CA: Iron homeostasis: new tales from the crypt. Blood (2000) 96:4020-4027.
18. PARKKILA S, WAHEED A, BRITTON RS et al.: Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc. Natl. Acad. Sci. USA (1997) 94:2534-2539.
19. WAHEED A, PARKKILA S, SAARNIO J et al.: Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc. Natl. Acad. Sci. USA (1999) 96:1579-1584.
20. ROY CN, PENNY DM, FEDER JN, ENNS CA: The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J. Biol. Chem. (1999) 274:9022-9028.
21. BENNETT MJ, LEBRON JA, BJORKMAN PJ: Crystal structure of the hereditary hemochromatosis protein HFE complexed with transferrin receptor. Nature (2000) 403:45-53.
22. FLEMING RE, MIGAS MC, ZHOU X et al.: Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transported DMT1. Proc. Natl. Acad. Sci. USA (1999) 96:3143-3148.
23. ZOLLER H, PIETRANGELO A, VOGEL W, WEISS G: Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transported DMT1. Lancet (1999) 353:2120-2123.
24. ANDERSON GJ: The control of iron absorption. J. Gastroenterol. Hepatol. (1996) 11:1030-1032.
25. OLYNYK JK, CULLEN DJ, AQUILLA S, ROSSI E, SUMMERVILLE L, POWELL LW: A population based study of the clinical expression of the hemochromatosis gene. N. Engl. J. Med. (1999) 341:718-724.
26. ADAMS PC, KERTESZ AE, VALBERG LS: Clinical presentation of hemochromatosis: A changing scene. Am. J. Med. (1991) 90:445-449.
27. MCDONNELL SM, PRESTON BL, JEWELL SA et al.: A survey of 2851 patients with hemochromatosis: Symptoms and response to treatment. Am. J. Med. (1999) 106:619-624.
28. BACON BR, SADIQ SA: Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am. J. Gast. (1997) 92:784-789.
29. TAVILL AS: Diagnosis and management of hemochromatosis. Hepatology (2001) 33:1321-1328.
30. BASSETT ML, HALLIDAY JW, FERRIS RA, POWELL LW: Diagnosis of hemochromatosis in young subjects: Predictive accuracy of biochemical screening tests. Gastroenterology (1984) 87:628-633.
31. MCCLAREN CE, BARTON JC, ADAMS PC et al.: Hemochromatosis and iron overload study research investigators. Hemochromatosis and iron overload screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am. J. Med. Sci. (2003) 325:53-62.
32. FARGION S, FRACANZANI AL, PIPERNO A et al.: Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology (1994) 20:1426-1431.
33. YAOUANQ JM: Diabetes and hemochromatosis: current concepts, management and prevention. Diabetes Metab. (1995) 21:319-329.
34. KELLY TM, EDWARDS CQ, MEIKLE AW, KUSHNER JP: Hypogonadism in hemochromatosis: reversal with iron depletion, Ann. Intern. Med. (1984) 101:629-632.
35. RIVERS J, GARRAHY P, ROBINSON W, MURPHY A: Reversible cardiac dysfunction in hemochromatosis. Am. Heart J. (1987) 113:216-217.
36. INES IS, DA SILAVA JA, MALCATA AB, PORTO AL: Arthropathy of genetic hemochromatosis: a major and distinctive manifestation of the disease. Clin. Exp. Rheum. (2001) 19:98-102.
37. VAN ASBECK BS, VERBRUGH HA, VAN OOST VA, MARX JJ, IMHOF HW, VERHOEF J: Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br. Med. J. (1982) 284:542-544.
38. CARNIEL E, MAZIGH D, MOLLARET HH: Expression of iron-regulated proteins in Yersinia species and their relation to virulence. Infect. Immun. (1987) 55:277-280.
39. BULLEN JJ, SPALDING PB, WARD CG, GUTTERIDGE JM: Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch. Intern. Med. (1991) 151:1606-1609.
40. SUGAR AM: Mucormycosis. Clin. Infect. Dis. (1992) 14(Suppl. 1):S126-S129.
41. KEBERLE H: The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. NY Acad. Sci. (1964) 119:758-765.
42. ROTHMAN RJ, SERRONI A, FARBER JL: Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidase cell injury. Mol. Pharmacol. (1992) 42:703-710.
43. PORTER JB, ABEYSINGHE RD, MARSHALL L, HIDER RC, SINGH S: Kinetics of removal and reappearance pf non-transferrin-bound plasma iron with deferoxamine therapy. Blood (1996) 88:705-713.
44. SUMMERS MF, JACOBS A, TUDWAY D, PERERA P, RICKETTS C: Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Haematol. (1979) 42:547-555.
45. DAVIS BA, PORTER JB: Long-term outcome of continuous 24-hour deferoxamine infusion via inswelling intravenous catheters in high-risk beta-thalassemia. Blood (2000) 95:1229-1236.
46. OLIVIERI NF, BRITTENHAM GM: Iron-chelating therapy and the treatment of thalassemia. Blood (1997) 89:739-761.
47. BRITTENHAM GM, GRIFFITH PM, NIENHUIS AW et al.: Efficacy of Deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med. (1994) 331:567-573.
48. OLIVIERI NF, BUNCIC RJ, CHEW E et al.: Visual and auditory neurotoxicity in patients receiving subcutaneious Deferoxamine infusions. N. Engl. J. Med. (1986) 314:869-873.
49. PIGA A, LUZZATTO L, CAPALBO P, GAMBOTTO S, TRICTA F, GABUTTI V: High dose desferrioxamine as a cause of growth failure in thalassaemic patients. Eur. J. Haematol. (1988) 40:380-381.
50. KOWDLEY KV, KAPLAN MM: Iron chelation therapy with oral deferiprone-toxicity or lack of efficacy? N. Engl. J. Med. (1998) 339:468-469.
51. FREEDMAN MH, GRISARU D, OLIVIERI NF, MACLUSKY I, THORNER PS: Pulmonary syndrome in patients with thalassemia major receiving intravenous Deferoxamine infusions. Am. J. Dis. Child. (1990) 144:565-569.
52. PORTER JB, JASWON MS, HUEHNS ER, EAST CA, HAZELL JW: Desferrioxamine ototoxicity: Evaluation of risk factos in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol. (1989) 73:403-409.
53. DRAGSTEN PR, HALLAWAY PE, HANSON GJ, BERGER AE, BERNARD B, HEDLUND BE: First human studies with a high-molecular-weight iron chelator. J. Lab. Clin. Med. (2000) 135:57-65.
54. BORGNA-PIGNATTI C, COHEN A: Evaluation of a new method of administration of the iron chelating agent deferoxamine. J. Pediatr. (1997) 130:86-88.
55. ARAUJO A, KOSARYAN M, MACDOWELL A et al.: A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload Br. J. Haematol. (1996) 93:835-837.
56. BARMAN BALFOUR JA, FOSTER RH: Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs (1999) 58:553-578.
57. OLIVIERI NF, KOREN G, MATSUI D et al.: Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator deferiprone in thalassemia intermedia. Blood (1992) 79:2741-2748.
58. OLIVIERI NF, BRITTENHAM GM, MATSUI D et al.: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N. Engl. J. Med. (1995) 332:918-922.
59. OLIVIERI NF, BRITTENHAM GM, MCLAREN CE et al.: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N. Engl. J. Med. (1998) 339:417-423.
60. HOFFBRAND AV, AL-REFAIE F, DAVIS B et al.: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood (1998) 91:295-300.
61. GIARDINA PJ, GRADY RW: Chelation therapy in beta-thalassemia: an optimistic update Semin Hema (2001) 38:360-366.
62. COHEN AR, GALANELLO R, PIGA A, DIPALMA A, VULLO C, TRICTA F: Safety profile of the oral iron chelator deferiprone: a multicenter study. Br. J. Haematol. (2000) 108:305-312.
63. GOGTEY J, AGARWAL MB, RAJADHYAKSHA G, MUNOT S: Deferiprone: A review of Indian study over 10 years, Proceedings of the 10th International Conference on Oral Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting, Limassol, Cyprus, March 22-26 (2000).
64. TONDURY P, NIELSEN P, FISCHER R, HIRT A: Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassemia patients, 1989-2000, Proceedings of the 10th International Conference on Oral Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting, Limassol, Cyprus, March 22-26 (2000).
65. LINK G, KONJIN AM, BREUER W, CABANTCHIK ZI, HERSHKO C: Exploring the 'iron shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J. Lab. Clin. Med. (2001) 138:130-138.
66. WONKE B, WRIGHT C, HOFFBRAND AV: Combined therapy with deferiprone and desferrioxamine. Br. J. Haematol. (1998) 103:361-364.
67. AYDINOK Y, NISLI G, KAVAKLI K, COKER C, KANTAR M, CETINGUL N: Sequential use of deferiprone and desferrioxamine in primary school children with thalassemia major in Turkey. Acta Hema (1999) 102:17-21.
68. HERSHKO C, KONJIN AM, NICK HP, BREUER W, CABANTCHIK ZI, LINK G: ICL670A: a new synthetic oral chelator; evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood (2001) 97:1115-1122.
69. BERGERON RJ, WIEGAND J, BRITTENHAM GM: HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic imn overload and acute iron poisoning. Blood (2002) 99:3019-3026.
70. WILSON SAK: Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain (1912) 34:295-509.
71. BRAMWELL B: Familial cirrhosis of the liver: four cases of acute fatal cirrhosis of the liver in the same family, the patients being respectively nine, ten, fourteen and fourteen years of age; suggested relationship to Wilson's progressive degeneration of the lenticular nucleus. Edin. Med. J. (1916) 17:90-99.
72. CUMINGS JN: The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain (1948) 71:410-415.
73. FRYDMAN M, BONNE-TAMIR B, FARRER LA, CONNEALLY PM, MAGAZANIK A, ASHBEL S, GOLDWITCH Z: Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus'. Proc. Natl. Acad. Sci. USA (1985):1819.
74. TANZI RE, PETRUKHIN KE, CHERNOV I et al.: The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet. (1993):344.
75. BULL PC, THOMAS GR, ROMMENS JM, FORBES JR, COX DW: The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. (1993):327.
76. HUNG IH, SUZUKI M, YAMAGUCHI Y, YUAN DS, KLAUSNER RD, GITLIN JD: Biochemical characterization of the Wilson disease protein and functional expression in he yeast Saccharomyces cerevisiae. J. Biol. Chem. (1997):21461.
77. SCHAEFER M, HOPKINS RG, FAILLA ML, GITLIN JD: Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver. Am. J. Physiol. Gastrointest Liver Physiol. (1999) 276:G639-G646.
78. MZHEL'SKAYA TI: Biological functions of ceruloplasmin and their deficiency caused by mutation in genes regulating copper and iron metabolism. Bull. Exp. Biol. Med. (2000) 130:719-727.
79. LOUDIANOS G, GITLIN JD: Wilson's disease. Semin. Liver Dis. (2000) 20:353-364.
80. COX DW, ROBERTS EA: Wilson disease. In: Gastrointestinal and liver disease. Vol. 2. Feldman M, Friedman LS, Sleisenger MH, (Eds), Saunders, Philadelphia, USA (2002):1269-1277.
81. PFEIL SA, LYNN DJ: Wilson's disease copper unfettered. J. Clin. Gastroenterol. (1999) 29:22-31.
82. MARTIN DA COSTA C, BALDWIN D, PORTMANN B, LOLIN Y, MOWAT AP, MIELE-VERGANI G: Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology (1992):609.
83. WALSHE JM, YEALLAND M: Chelation treatment of neurological Wilson's disease. QJ Med. (1993) 86:197-204.
84. SCHILSKY M: Diagnosis and treatment of Wilson's disease. Pediatr. Transplant. (2002) 6:15-19.
85. BREWER GJ: Zinc acetate for the treatment of Wilson's disease. Expert Opin. Pharmacother. (2001) 2:1473-1477.
86. WALSHE JM: Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med. (1956) 21:487-495.
87. PHYSICIANS' DESK REFERENCE: Vol. 1. Montvale: Medical Economics Company, Inc., (2002):3635.
88. MJOLNEROD OK, DOMMERUD SA, RASMUSSEN K, GJERULDSEN ST: Congential connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet (1971) 1:673-675.
89. SOLOMON L, ABRAMS G, DINNER M, BERMAN L: Neonatal abnormalities associated with d-penicillamine treatment during pregnancy. N. Engl. J. Med. (1977) 296:54-55.
90. HSU H, HUANG F, NI Y, CHANG M: Steroids used to desensitize penicillamine allergy in Wilson disease. Acta Paediatr. (1999) 40:448-450.
91. SVETEL M, STERNI N, PEJOVI S, KOSTI VS: Penicillamine-induced lethal status dystonicus in a patient with Wilson's disease. Mov. Disord. (2001) 16:568-569.
92. HUANG CC, CHU NS: Wilson's disease: resolution of MRI lesions following long-term oral zinc therapy. Acta Neurol. Scand. (1996) 93:215-218.
93. BREWER GJ: Pencillamine should not be used as initial therapy in Wilson's disease. Mov. Disord. (1999) 14:551-554.
94. GIBBS KR, WALSHE LM: In: Orphan diseases and orphan drugs. Scheinberg IH, Walshe JM (Eds), Manchester University Press, London, UK (1986):33-42.
95. KODAMA H, MURATA Y, IITSUKA T, ABE T: Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci. (1997) 61:899-907.
96. WALSHE JM, COX DW: Effects of treatment of Wison's disease on natural history of haemochromatosis. Lancet (1998) 352:112-113.
97. PERRY AR, PAGLIUCA A, FITZSIMONS EJ, MUFTI GJ, WILLIAMS R: Acquired sideroblastic anaemia induced by copper-chelating agent. Int. J. Hematol. (1996) 64:69-72.
98. KEEN CL, LONNERDAL B, HURLEY LS: Teratogenic effect of copper deficiency and excess. In: Inflammatory diseases and Copper. Sorenson JRJ (Ed.), Humana Press, Clifton NJ, USA (1982):109-121.
99. BREWER GJ, JOHNSON VD, DICK RD, FINK JK, KLUIN KJ, HEDERA P: Treatment of Wilson's disease with zinc XVII: Treatment during pregnancy. Hepatology (2000) 31:364-370.
100. SCHOUWINK G: De hepato-cerebrale degeneratic (met een onderzoek van de zinkstofwisseling). Arnhem, Van der Wiel (1961).
101. HOOGENRADD TU, VAN DEN HAMER CJA: Three years of continuous zinc therapy in four patients with Wilson's disease. Acta Neurol. Scand. (1983) 67:356-264.
102. BREWER GJ, DICK RD, JOHNSON VD, FINK JK, KLUIN KJ, DANIELS S: Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. J. Lab. Clin. Med. (2001) 137:191-198.
103. FOOD AND DRUG ADMINISTRATION: Teratologic evaluation of FDA 71-49 (zinc sulfate). Food and Drug Administration, United States Department of Commerce Publications PD-221 805 (1973).
104. BREWER GJ, YUZBASIYAN-GURKAN V, JOHNSON V, DICK RD, WANG Y: Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J. Am. Col. Nutr. (1993) 12:26-30.
105. ESMAELI B, BURNSTINE MA, MARTONYI CL, SUGAR A, JOHNSON V, BREWER GJ: Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease. Cornea (1996) 15:582-588.
106. BREWER GJ, DICK RD, JOHNSON VD, BRUNBERG JA, KLUIN KJ, FINK JK: Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J. Lab. Clin. Med. (1998) 132:264-278.
107. OGRA Y, KOMADA Y, SUZUKI KT: Comparative mechanism and toxicity of tetre- and dithiomolybdates in the removal of copper. J. Inorg. Biochem. (1999):199-204.
108. 4) as an 'anti-copper' agent in man. In: Orphan diseases and orphan drugs (Vol. 1) Scheinberg IH, Walshe JM (Eds), Manchester University Press, Manchester, UK (1986):68-75.
109. BREWER GJ, JOHNSON V, DICK RD, KLUIN KJ, FINK JK, BRUNBERG JA: Treatment of Wilson disease with ammonium tetrathiomolybdate: II. initial therapy in 33 neurologically affected patients and follow-up with zinc therapy [original contribution]. Arch. Neurol. (1996) 53:1017-1025.
110. KARUNAJEEWA H, WALL A, METZ J, GRIGG A: Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust. NZ J. Med. (1998) 28:215-216.
111. CUMINGS JN: The effect of BAL in hepato-lenticular degeneration. Brain (1951) 74:10-22.
112. DENNY BROWN D, PORTER H: The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N. Engl. J Med. (1951) 245:917-925.
113. MUCKTER H, LIEBL B, REICHL F, HUNDER G, WALTHER U, FICHTL B: Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Hum. Exp. Toxicol. (1997) 16:460-465.
114. MINGSHAN R, RENMIN Y: Clinical curative effects of dimercaptusuccinic acid on hepatolenticular degeneration and the impact of DMSA on biliary trace elements. Chin. Med. J. (Engl) (1997) 110:694-697.